NCT06221618

Brief Summary

Coronary heart disease(CHD), stroke, and hypertension are major diseases that seriously affect human health.Pathologic changes in the arteries involved in the above diseases mainly occur in the intimal or medial layer of the arteries. Among them, cardiovascular and cerebrovascular diseases (CHD and stroke) have become the top two causes of death worldwide, with elderly patients accounting for the vast majority. CHD is an important cause of death, and atherosclerosis (AS) is the main pathology underlying it.AS predominantly occurs in the intima layer, and the use of high-resolution imaging techniques to visualize anatomical changes in the intima-media layer of the arteries alone is valuable for the study of AS. Coronary computed tomographic angiography (CCTA) and intracranial vascular magnetic resonance angiography (MRA) can clearly visualize coronary and intracranial arterial lesions, measure luminal stenosis and other important information, and provide a basis for diagnosis, treatment and prognosis of the disease. By integrating CCTA/MRA/Ultrasound multimodal imaging technology, investigators aim to develop a non-invasive CHD and stroke intelligent screening and evaluation system, which is bound to have great clinical and social value. This study is a national multi-center follow-up observational study, which is expected to collect and establish a database of clinical and imaging information of no less than 20,000 cases of elderly subjects. Some data is derived from the pre-established database (\>12,000 cases) in cooperative research centers, while additional data will be collected from the newly established prospective follow-up database. Investigators performed noninvasive high-frequency ultrasound to detect arterial vascular structural changes, vascular dynamics and other indicators based on the existing database and the newly established imaging database to explore the characteristics of carotid atherosclerosis changes and ultrasound monitoring methods in the elderly. Finally, investigators integrated clinical and multimodal noninvasive imaging information to construct a noninvasive imaging-based intelligent risk assessment system for CHD and stroke. Primary endpoint was the cardiovascular-complex endpoint event,including myocardial infarction, cardiovascular death, resuscitation with cardiac arrest, revascularization, and stroke. Secondary endpoint was vascular lesion progression, including increase of vascular intima thickness, increase of vascular media thickness, plaque progression, and increase of vascular stenosis. All enrolled patients were followed up every six months to record whether the primary endpoint and secondary endpoint events occurred and to record the time and type of occurrence.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
8,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2024

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 18, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 24, 2024

Completed
22 days until next milestone

Study Start

First participant enrolled

February 15, 2024

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

January 24, 2024

Status Verified

December 1, 2023

Enrollment Period

1.7 years

First QC Date

December 18, 2023

Last Update Submit

January 14, 2024

Conditions

Keywords

StrokeCoronary heart diseaseRisk assessmentMultimodality imagingCardiovascular diseases

Outcome Measures

Primary Outcomes (1)

  • Cardiovascular and cerebrovascular composite endpoint events

    * Myocardial infarction * Cardiovascular death * Resuscitation with cardiac arrest * Revascularization * Stroke.

    From the date of enrollment until the date of the first recorded endpoint event or the date of the end of the study, up to 20 months

Secondary Outcomes (1)

  • Progression of the vascular lesions

    From the date of enrollment until the date of the first recorded endpoint event or the date of the end of the study, up to 20 months

Study Arms (3)

Coronary heart disease cohort

CCTA required for coronary heart disease cohort

Other: High-frequency carotid arteries ultrasound, CCTA, Cranial MRA

Stroke cohort

Cranial MRA required for stroke cohort

Other: High-frequency carotid arteries ultrasound, CCTA, Cranial MRA

Normal control group

Healthy elderly without coronary heart disease and stroke (≥ 60 years old)

Other: High-frequency carotid arteries ultrasound, CCTA, Cranial MRA

Interventions

CCTA and carotid high-frequency ultrasound for all patients in the coronary heart disease cohort. Cranial MRA and carotid high-frequency ultrasound for all people in the stroke cohort.Carotid high-frequency ultrasound for all patients in the normal control group.All patients were treated optimally according to guidelines

Coronary heart disease cohortNormal control groupStroke cohort

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients come from the following hospitals: * Qilu Hospital of Shandong University, * Xuanwu Hospital of Capital Medical University, * Chinese PLA General Hospital * Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine * Shenzhen People's Hospital * The Fourth Affiliated Hospital of China Medical University.

You may qualify if:

  • Age ≥ 60 years
  • All patients had original ultrasound images of bilateral carotid arteries with DICOM format and arteriosclerosis clinical and laboratory data
  • Original data of CCTA or examination results in the baseline status are needed for CHD patients
  • Original data of intracranial artery MRA or examination results in the baseline status are needed for patients with ischemic stroke.

You may not qualify if:

  • Age is \<60 years old
  • Severe cardiac insufficiency, New York Heart Association(NYHA) class IV and (or) left ventricular ejection fraction \<30%
  • Uncontrollable severe hypertension (systolic blood pressure≥ 180 mmHg or diastolic blood pressure≥ 110 mmHg) or uncontrollable severe diabetes mellitus, i.e., diabetes mellitus complicated with acute complications (including diabetic ketoacidosis and hypertonic hyperglycemic nonketosis coma), or acute hyperglycemic state (random blood glucose\> 16.7mmol/L and (or) blood ketone 1.0-3.0mmol/L) without acute complications
  • Severe valvular disease (moderate regurgitation and / or stenosis in each valve)
  • Various cardiomyopathy caused by hypertrophic cardiomyopathy, dilated cardiomyopathy, alcoholic cardiomyopathy, myocardial amyloidosis
  • Severe arrhythmia: persistent atrial fibrillation or atrial flutter, degree II 2 and above atrioventricular block, complete left bundle branch block
  • Severe hepatic and renal insufficiency (glutamate transaminase and / or glutamine transaminase\> 3 times the upper limit of normal value, Blood creatinine\> 134 μmol/L or an estimated glomerular filtration rate of \<60ml/min/1.73m2)
  • Severe chronic obstructive pulmonary disease or asthma
  • Severe non-cardiovascular disease (malignant tumor, thyroid disease, infection, connective tissue disease)
  • Mental retardation or mental disorders
  • Life expectancy \<3 years due to various factors
  • Refusal to sign informed consent
  • Allergy to contrast agent should also be ruled out for patients undergoing CCTA for CHD.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mei Zhang

Jinan, Shandong, China

Location

Related Publications (3)

  • Lusis AJ. Atherosclerosis. Nature. 2000 Sep 14;407(6801):233-41. doi: 10.1038/35025203.

    PMID: 11001066BACKGROUND
  • Schoenhagen P, Vince DG. Intravascular photoacoustic tomography of coronary atherosclerosis: riding the waves of light and sound. J Am Coll Cardiol. 2014 Jul 29;64(4):391-3. doi: 10.1016/j.jacc.2014.05.018. No abstract available.

    PMID: 25060375BACKGROUND
  • Ruengsakulrach P, Sinclair R, Komeda M, Raman J, Gordon I, Buxton B. Comparative histopathology of radial artery versus internal thoracic artery and risk factors for development of intimal hyperplasia and atherosclerosis. Circulation. 1999 Nov 9;100(19 Suppl):II139-44. doi: 10.1161/01.cir.100.suppl_2.ii-139.

    PMID: 10567293BACKGROUND

MeSH Terms

Conditions

AtherosclerosisStrokeCoronary DiseaseCardiovascular Diseases

Condition Hierarchy (Ancestors)

ArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMyocardial IschemiaHeart Diseases

Study Officials

  • Mei Zhang, PhD

    Qilu Hospital of Shandong University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mingjun Xu, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 18, 2023

First Posted

January 24, 2024

Study Start

February 15, 2024

Primary Completion

October 31, 2025

Study Completion

December 31, 2025

Last Updated

January 24, 2024

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share

Locations